New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
04:55 EDTATOS, ATOS, RHHBY, RHHBY, SQNM, SQNM, GHDX, GHDX, SAP, SAP, AET, AET, IBM, IBM, UNH, UNHPMWC, Inc to host a conference
Personalized Medicine World Conference is being held in Mountain View, California on January 28-29.
News For ATOS;RHHBY;SQNM;GHDX;SAP;AET;IBM;UNH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 19, 2014
17:42 EDTIBMIBM to make 'major business announcement'
Subscribe for More Information
October 17, 2014
10:00 EDTIBMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTUNHOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AK Steel (AKS) upgraded to Buy from Neutral at Nomura... AMD (AMD) upgraded to Sector Perform from Underperform at Pacific Crest... Atlantic Power (AT) upgraded to Market Perform from Underperform at BMO Capital... Basic Energy (BAS) upgraded to Outperform from Market Perform at Cowen... BorgWarner (BWA) upgraded to Buy from Hold at Deutsche Bank... CA Technologies (CA) upgraded to Overweight from Equal Weight at Barclays... Calumet Specialty Products (CLMT) upgraded to Outperform at Wells Fargo... DHT Holdings (DHT) upgraded to Buy from Hold at Evercore... Exelon (EXC) upgraded to Neutral from Sell at Citigroup... Fifth Third Bancorp (FITB) upgraded to Buy from Neutral at Citigroup... Goldman Sachs (GS) upgraded to Outperform from Market Perform at Keefe Bruyette... Helmerich & Payne (HP) upgraded to Buy from Neutral at UBS... Hilton (HLT) upgraded to Buy from Neutral at SunTrust... Hyatt Hotels (H) upgraded to Outperform from Neutral at Macquarie... IPG Photonics (IPGP) upgraded at Stifel... ITC Holdings (ITC) upgraded to Neutral from Underperform at Credit Suisse... Manpower (MAN) upgraded to Outperform from Market Perform at Avondale... Nabors Industries (NBR) upgraded to Outperform from Market Perform at Cowen... Newpark Resources (NR) upgraded at Cowen... Old Dominion (ODFL) upgraded to Buy from Neutral at Longbow... PDC Energy (PDCE) upgraded at SunTrust... Patterson-UTI (PTEN) upgraded to Buy from Neutral at UBS... PrivateBancorp (PVTB) upgraded to Outperform from Neutral at Macquarie... QLogic (QLGC) upgraded to Buy from Hold at Summit Research... RPC, Inc. (RES) upgraded at Cowen... Sonoco (SON) upgraded to Neutral from Underperform at DA Davidson... Southwestern Energy (SWN) upgraded to Outperform from Market Perform at Raymond James... SunEdison (SUNE) upgraded to Outperform at Cowen... TSMC (TSM) upgraded to Buy from Neutral at Mizuho... Tesco (TESO) upgraded to Outperform from Market Perform at Cowen... UnitedHealth (UNH) upgraded to Outperform from Market Perform at Leerink... Xilinx (XLNX) upgraded to Outperform from Market Perform at Wells Fargo.
07:33 EDTIBMIBM reinstated with a Neutral at BofA/Merrill
Target $200.
07:27 EDTUNHUnitedHealth upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information
06:09 EDTUNHUnitedHealth upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information
October 16, 2014
14:47 EDTRHHBYRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
13:13 EDTRHHBYRoche considers submitting Ebola test for emergency use approval, WSJ says
Subscribe for More Information
09:35 EDTRHHBYDiplomat announces contract to distribute Esbriet
Subscribe for More Information
09:29 EDTUNHUnitedHealth contines to see stable trends across businesses
Subscribe for More Information
09:23 EDTUNHOn The Fly: Pre-market Movers
Subscribe for More Information
09:21 EDTIBMIBM volatility elevated into Q3 results
IBM October weekly call option implied volatility is at 35, November is at 27, January is at 22; compared to its 26-week average of 19 into the expected release of Q3 results on October 20.
09:12 EDTUNHUnitedHealth expects top, bottom-line growth acceleration in next two years
Says seeing steady progress across all businesses. Believes products well positioned locally. Says on-course to participate in 2 dozen state exchanges in FY15. Says consensus estimates for FY15 outlook are "well calibrated". Says "feels good" about the company's FY15 position. Expects to grow meaningfully at sustainable margins in FY15. Expects to grow earnings across the board for FY15. Says all of its businesses are better positioned for FY15 as opposed to FY14. Says Obamacare exchange business is expected to be profitable in FY15. Says Optum unit sales will be above targets. Says will grow y just under 1M Medicaid members this year. Comments made during the company's Q3 earnings conference call.
07:57 EDTSAPSalesforce president lays out vision for quadrupling revenue, WSJ reports
Salesforce (CRM) president and vice chairman Keith Block outlined his plan to grow the company's annual revenue to $20B at the company’s annual Dreamforce conference, said The Wall Street Journal, which noted that Block specifically said, “We want to be bigger than SAP.” Block's strategy involves expansion in new product areas, adding new packages of software tailored to a handful of high-value industries, and expanding sales efforts outside of North America, the Journal reported. Reference Link
06:10 EDTUNHUnitedHealth reports Q3 Employer & Individual revenue $10.6B
Subscribe for More Information
06:08 EDTUNHUnitedHealth: Affordable Care Act reduced Q3 by 80 basis points
Subscribe for More Information
06:07 EDTUNHUnitedHealth sees FY14 EPS $5.60-$5.65, consensus $5.58
Subscribe for More Information
06:01 EDTUNHUnitedHealth reports Q3 EPS $1.63, consensus $1.53
Subscribe for More Information
05:58 EDTRHHBYRoche sees FY14 core EPS targeted to grow ahead of sales
Subscribe for More Information
05:56 EDTRHHBYRoche reports 9 month revenue CHF34.76B vs. CHF34.87B last year
Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use